

The development of biosimilars in a clinical setting can be a costly and time-consuming process. Given the competitive nature of this market, it is crucial to plan ahead and apply the lessons and knowledge gained from past biosimilars and novel product development, in order to streamline the process as predictable and increased efficiency.
In this session, IQVIA experts will provide valuable insights into upcoming biosimilars opportunities in the market, expected challenges and emerging trends in development, lessons learned from successful biosimilars development over the past two decades, strategies to effectively leverage various types of data, and advice on developing and collaborating with appropriate clinical trial sites.
Charu Manaktala MD
Senior Medical Director and Head, Biosimilars Center of Excellence, IQVIA
Supriya Chauhan
Therapeutic Strategy Director, Clinical Development & Operation Strategy, IQVIA
Alexander Kant MSc
Director, Clinical Trial Analytics & Strategic Insights, IQVIA
Radoslaw Jadczak MD, PhD, MBA
Director, Early Phase Oncology Therapeutics Network, IQVIA